phy and congestive heart failure; and is associated with improved metabolic parameters. [3] [4] [5] [6] RKF is referred to as the "heart of PD"; however, very few studies have analyzed the relation between RKF and mortality and other important outcomes in HD patients. 4, 7, 8 The National Kidney Foundation's KDOQI (Kidney Disease Outcomes Quality Initiative) 2006 guidelines recommend "striving to preserve RKF in HD patients (grade A recommendation)" and ranked clinical outcomes research for RKF as a "Critical Research Recommendation." 9 However, RKF is difficult to assess and is measured in Ͻ5% of HD patients, limiting outcomes research. 10 Urine output may serve as a simple indicator of RKF in HD patients.
The objective of this study is to determine the association of urine output with mortality, quality of life (QOL), and inflammation in incident HD patients participating in the CHOICE (Choices for Healthy Outcomes in Caring for End-Stage Renal Disease) Study.
METHODS

Study Design
The CHOICE Study is a nationally representative prospective cohort study of incident dialysis patients. 11 From October 1995 to June 1998, a total of 1,041 participants from 19 US states were enrolled, 767 of whom were on HD therapy. CHOICE patients were followed up through December 31, 2004 . Eligibility criteria were new onset of long-term dialysis therapy in the preceding 3 months, ability to provide informed consent, age older than 18 years, and ability to speak English or Spanish. The Johns Hopkins Medicine Institutional Review Board (Baltimore, MD) and the clinical centers' review boards approved the study.
Data Collection
Exposure RKF was assessed using the self-described ability to produce at least 1 full cup (250 mL) of urine daily and was ascertained from study questionnaires at baseline and followup. Information about urine output was available for 734 of 767 (96%) participants at baseline. During the first year, 60 participants died and 36 underwent transplant. Of the remaining participants, 579 (91%) had information available about urine output at year 1. Characteristics of those with missing urine output information were analyzed. Measured urine volume was available for a subsample (42%) of participants at baseline and was used to validate self-reported urine output.
Outcomes
Primary outcomes were all-cause and cardiovascular disease (CVD) mortality. Mortality information was adjudicated using information from clinic reports, medical records, the National Death Index, Centers for Medicare & Medicaid Services (CMS) death notification forms, and Social Security records. 12 Secondary outcomes were QOL, inflammation, and erythropoietin (EPO) dose requirement. QOL scores were obtained from the CHOICE Health Experience Questionnaire (CHEQ), a validated patient self-report questionnaire completed at baseline and year 1. 13 The presence of inflammation was assessed in a subset of participants (n ϭ 655) by measuring high-sensitivity C-reactive protein (CRP) using a colorimetric competitive enzyme-linked immunosorbent assay (coefficient of variation, 8.9%) and interleukin 6 (IL-6), a proinflammatory cytokine, measured using an ultrasensitive enzyme-linked immunosorbent assay (coefficient of variation, 7%). Average weekly EPO dose during the first 6 months after enrollment was calculated from US Renal Data System (USRDS) medical evidence and claims data. EPO resistance index was calculated by dividing average weekly EPO dose by hemoglobin concentration (in grams per deciliter).
Other Variables
All participants provided information about demographics, work history, medical history, and predialysis care. Body mass index (weight (in kg)/[height (in m)]
2 ) was based on the height and weight reported on the 2728 form. Late referral was defined as less than 4 months between the first nephrologist evaluation and start of dialysis therapy. Comorbid conditions were assessed using the Index of Coexistent Disease (ICED), a validated medical record-derived index that captures both the presence and severity of comorbid conditions. 14,15 ICED scores range from 0-3, with 3 as the highest severity level. Data for the use of diuretics, calcium channel blockers, and angiotensin-converting enzyme (ACE) inhibitors were abstracted from patient charts. Laboratory data from routine patient care were available for serum albumin, calcium, phosphorus, potassium, ferritin, transferrin saturation, and hemoglobin. Dialysis dose (Kt/V) was calculated using the Daugirdas formula. 16 
Statistical Analysis
Baseline characteristics of participants were compared based on urine output status at baseline and year 1 using Pearson 2 test, t test, or robust regression, as appropriate. Survival analysis techniques were used to analyze the risk of mortality based on urine output. Individuals were censored at transplant or end of the study period (December 31, 2004). The cumulative incidence of all-cause and CVD mortality was calculated using the Kaplan-Meier product-limit estimator. Cox proportional hazards regression, stratified by dialysis clinics, was used to model the risk of death based on urine output status at baseline and year 1. Proportional hazards assumptions were checked graphically and using hypothesis-based tests. Hazard ratios (HRs) were calculated to assess the risk of death in unadjusted models and after adjustment for a priori-defined confounders, including: (1) Missing data for variables were as follows: educational status (0.9%), smoking history (0.6%), body mass index (6.7%), pulse pressure (4.9%), and serum albumin at baseline (1.6%) and year 1 (5.9%). Missing data values were imputed with 10 data replicates using multiple imputation by the chained equations method implemented using the ice program in Stata 10.1 (Stata Corp, www.stata. com). Multivariate linear regression was used to model the association between urine output and QOL, inflammation (CRP and IL-6 levels), and EPO dose. Logistic regression was used to determine the odds of preserved urine output at year 1 with the use of diuretics, calcium channel blockers, or ACE inhibitors. Statistical analyses were performed using Stata software, version 10.1. Statistical significance was defined as P Ͻ 0.05 using 2-tailed tests.
RESULTS
Participant Characteristics
Baseline characteristics of participants stratified by urine output at baseline and year 1 are listed in Table 1 . Individuals with urine output were more likely to be white, have undergone earlier nephrologist evaluation, have higher systolic blood pressure and pulse pressure, and be receiving diuretics compared with those without urine output. Participants with missing urine output information at baseline (n ϭ 33 [4%]) were more likely to be older (P ϭ 0.008) and have more comorbid conditions (P ϭ 0.004), including prevalent CVD (P ϭ 0.009) and history of congestive heart failure (P ϭ 0.05). At year 1, those with missing urine output information (n ϭ 60 [9%]) were more likely to have higher pulse pressure (P ϭ 0.03) and less likely to have finished high school (P ϭ 0.01).
All-Cause Mortality
Of the 734 CHOICE participants at baseline, 481 (66%) died during 2,657 person-years of follow-up (median, 3.2 years). The protective effect of urine output on mortality was most pronounced for individuals with the presence of urine output at year 1 (Fig 1A and B) .
The incidence rate of all-cause mortality and adjusted relative hazards are listed in Table 2 . Baseline urine output was not associated with improved survival. Urine output at baseline and year 1, indicating preserved RKF, was associated with a 35% lower risk of death in unadjusted models, and this protective effect persisted even after extensive adjustment for putative confounders, including demographic, clinical, and treatment characteristics (adjusted HR, 0.70; 95% confidence interval [CI], 0.52-0.93).
We also analyzed the effect of change in residual urine output during year 1 on mortality (Table 3) . Preserved urine output (urine output at baseline and year 1; n ϭ 163) was associated with 31% lower risk of all-cause mortality (HR, 0.69; 95% CI, 0.51-0.93) compared with loss of RKF (urine output at baseline, but not year 1; n ϭ 319). A weaker association was noted comparing preserved urine output with the group with no urine output at baseline or year 1.
CVD Mortality
CVD deaths accounted for 48% of all deaths. Overall, trends were similar to those for all-cause mortality. Preserved urine output was associated with improved survival; however, results did not reach statistical significance (Fig 1C and D ; Table 2 ).
Quality of Life
Participants with urine output at baseline reported overall better QOL (P ϭ 0.05) and less dietary restriction (P ϭ 0.05). Analyses are provided in more detail in Item S1, available as online supplementary material associated with this article at www.ajkd.org.
Inflammation and EPO Dose Requirement
The presence of urine output was associated with lower levels of inflammatory markers (Table  1) . CRP levels were lower in participants with urine output at baseline compared with those without (median difference, Ϫ0.37 mg/dL; P ϭ 0.02). Similar differences were observed with IL-6 levels. At year 1, the highest CRP levels were noted in participants who did not have urine output at baseline or year 1 (median, 1.06; 25th-75th percentiles, 0.41-1.75); intermediate in those with urine output at baseline, but not year 1 (median, 0.91; 25th-75th percentiles, 0.33-2.38); and lowest in those with urine output at baseline and year 1 (median, 0.63; 25th-75th percentiles, 0.25-1.61; adjusted P trend ϭ 0.006).
Mean EPO dose during the first 6 months after enrollment was available for 416 (57%) partici- Similar trends were noted with the EPO resistance index (Table 1) . Both urine output groups had adequate iron stores, assessed using ferritin and transferrin saturation, at baseline and year 1.
Sensitivity Analyses
Analysis without data imputation yielded results similar to the primary analysis (data not shown). Kt/V information was available for 77% of participants at baseline. Adjusting for Kt/V did not change results. Further adjustment for putative mediators of RKF, identified a priori, including hemoglobin, potassium, calcium, and phosphate levels, did not change results (HR for all-cause mortality risk with urine output at year 1, 0.73; 95% CI, 0.54-0.99; P ϭ 0.05). In the subset of patients with urine volume measurements (n ϭ 306 [42%]), median urine volumes were 400 mL/d (25th-75th percentiles, 200-625) in those reporting less than 1 cup of urine per day (n ϭ 281; 92%) and 725 mL/d (25th-75th percentiles, 500-1,160) in those reporting more than 1 cup of urine per day (P Ͻ 0.001). Those on diuretic therapy had higher urine volumes (mean, 228 mL/d higher; P ϭ 0.03). Analysis of the subset of participants with urine volume measurement at baseline showed results similar to the primary analysis (adjusted HR for all-cause mor- tality per 250 mL/d of urine, 0.93 [95% CI, 0.87-1.0]; P ϭ 0.04). Although diuretic use was higher in those with urine output at baseline and year 1, diuretic use at baseline was not associated with preserved urine output at year 1 (adjusted odds ratio [OR], 1.55; 95% CI, 0.75-3.23; P ϭ 0.2). ACE inhibitor use was also not associated with preserved urine output at year 1 (adjusted OR, 0.91; 95% CI, 0.57-1.47; P ϭ 0.7). Nineteen individuals reported urine output less than 1 cup at baseline and more than 1 cup at year 1. These individuals were reclassified as producing more than 1 cup at baseline. Analyses performed excluding these individuals showed results similar to the primary analysis (data not shown).
DISCUSSION
To date, very few large representative studies have reported on the role of RKF in HD patients, particularly in the United States. This analysis of urine output from a national prospective cohort study of incident dialysis patients shows several important findings. RKF, identified using selfreported urine output, was reliable and was independently associated with lower all-cause mortality in HD patients. The survival benefit was especially notable in participants who had preserved urine output during year 1. Urine output also was associated with better QOL, lower inflammation measured using CRP and IL-6 levels, and lower EPO use.
RKF is well recognized as an important and independent predictor of survival in PD patients. In 680 PD participants in the CANUSA (Canada-USA) Study, each 1-mL/min/1.73 m 2 higher estimated GFR (eGFR) was associated with a 23% lower risk of death. 17 Urine volume appeared to mediate this effect with a 36% lower risk of mortality per 250 mL (1 cup) of urine output per day. In 413 PD participants in NECOSAD (The Netherlands Cooperative Study of Dialysis), each 1-mL/ min/1.73 m 2 higher eGFR was associated with 12% lower mortality. 18 Similarly, in 965 participants in the ADEMEX (Adequacy of Dialysis in Mexico) Trial, each 1-mL/min/1.73 m 2 higher eGFR was associated with 11% lower risk of death. 19 RKF seems to have an equally important role in HD patients, but is not routinely assessed or reported. In a single-center US study of 114 prevalent HD patients, the presence of any urine output (Ͼ100 mL/d) was associated with a 65% lower risk of death during the subsequent 2-year period. 8 In 740 incident HD participants in NECOSAD, 56% lower mortality was noted per 1-week higher renal urea Kt/V during a median follow-up of 1.7 years. 4 In another single-center study of 650 incident HD patients at the Lister Renal Unit in the United Kingdom, individuals with urea clearance Ն1 mL/min at 6 months had 31% lower mortality compared with those with urea clearance Ͻ1 mL/min. 20 Our study adds robustness to these previously reported studies with a national cohort representative of the US HD population, 21 prospective design, long followup, and meticulous assessment of comorbid conditions, laboratory data, and outcomes, allowing for extensive adjustment for confounders. Moreover, it shows that a simply obtained patientreported crude measure of urine output (producing "1 cup of urine") is reliable and predicts prognosis. More precise measurements often are difficult to obtain and sometimes are thwarted by patient nonadherence and/or obvious dialysis unit "burden." a Yes refers to the ability to produce at least 250 mL (1 cup) of urine daily. b P value for incidence rate ratio or HR; participants without urine output is the comparison group. c Cox proportional hazards regression stratified by clinic. d Demographic characteristics: age, race (white or other), sex, educational status (completed high school or not), marital status (married or not), and employment status (employed or not employed).
e Clinical and treatment factors in addition to demographic characteristics: smoking history (ever smoked), pulse pressure, body mass index, primary cause of kidney failure (diabetes, hypertension, glomerulonephritis, or other), Index of Coexistent Disease score (0-3), cardiovascular disease, congestive heart failure, left ventricular hypertrophy, diabetes, and serum albumin level (at baseline or year 1).
In the context of PD therapy, it is well known that RKF contributes significantly to QOL. 18 To our knowledge, this is the first time that an association between urine output and QOL has been shown in patients treated with HD. Patients with urine output reported greater vitality, better cognitive function, and fewer dietary restrictions during year 1.
RKF in HD patients may prevent volume overload and its sequelae, including left ventricular hypertrophy and uncontrolled hypertension.
1,2,5,22-25 RKF, even at the low levels present in dialysis patients, can provide a substantial level of clearance for solutes, such as ␤ 2 -microglobulin, p-cresol, and indican. 26, 27 In the HEMO Study, each 1-mL/min higher renal urea clearance was associated with a 7.2-mg/L lower ␤ 2 -microglobulin level. 28 Loss of RKF also is associated with higher levels of CRP, IL-6, and other inflammatory markers, such as soluble vascular adhesion molecule and neopterin.
29, 30 The presence of inflammation in dialysis patients is associated with all-cause and CVD mortality, as well as a faster decrease in RKF. [31] [32] [33] [34] [35] [36] In our study, participants with preserved RKF (urine output at baseline and year 1) had lower levels of inflammatory markers and improved survival independent of potential confounders.
We noted decreased EPO requirements in participants with urine output, and the effect was especially pronounced in participants with preserved urine output during year 1. All urine output groups had adequate iron stores, assessed using ferritin and transferrin saturation. Weekly EPO dose was 12,000 U/wk lower in those with preserved urine output at year 1 (P ϭ 0.001). The EPO resistance index also was lower in participants with urine output, suggesting lower EPO resistance or greater endogenous EPO production. Similar findings were noted in the Lister Renal Unit cohort. For individuals with urea clearance Ն1 mL/min compared with those with urea clearance Ͻ1 mL/min, EPO dose was 1,993 U/wk lower at 12 months and 2,238 U/wk lower at 24 months (P Ͻ 0.001 at each time). 20 In 2005, outpatient payments by Medicare for EPO amounted to $1.9 billion and represented approximately 25% of the total end-stage renal disease payments. 37 Our study suggests that preservation of RKF may decrease dialysis-related expenses while improving survival. However, this hypothesis needs to be tested in randomized clinical trials.
Blockade of the renin-angiotensin system is considered standard therapy to preserve RKF in PD patients. 38 Much less is known about preservation of RKF in HD patients. In an analysis of 811 HD participants in the USRDS Dialysis Morbidity and Mortality Study (DMMS) Wave 2, use of ACE inhibitors showed a trend toward preservation of RKF (adjusted OR, 0.7; P ϭ 0.06). 10 Other medications, such as diuretics and calcium channel blockers, had no effect on RKF. However, in an analysis of 16,420 HD patients from the DOPPS (Dialysis Outcomes and Practice Patterns Study), diuretic use was associated with 2-fold higher odds of preserved RKF at year 1 (OR, 1.93; P ϭ 0.01). 39 In our study, participants with urine output were more likely to be using a diuretic; however, neither diuretics nor ACE inhibitors were associated with preserved urine output at year 1. Although diuretic use may be associated with increased urine volume, it is more likely, based on data in non-end-stage renal disease and PD patients, that ACE inhibitors may have a greater long-term protective effect on RKF. With the emerging importance of RKF in HD patients, randomized controlled trials are needed to address this important question.
Our study has several important limitations. First, urine output was not measured directly in the study and is based on self-report. Participants were asked about their ability to produce 1 cup (250 mL) of urine daily in questionnaires at baseline and year 1. We validated the self-report using measured urine volume in a subset of participants (n ϭ 306; 42%). Individuals who reported less than 1 cup of urine output per day (n ϭ 25) had approximately half the urine volume of individuals who reported more than 1 cup of urine output per day (n ϭ 281). Because urine collections were part of routine clinical care at dialysis units, it is highly likely that the individuals reporting no urine output or minimal amounts were not asked to collect urine. Based on prior studies, the presence of any urine output is a strong predictor of survival, as we also showed in this study. 8, 20 Second, the presence of RKF may be a reflection of better overall health, and the survival benefit seen in those with preserved urine output in our study may represent survival due to fewer comorbid conditions. However, we did not notice a difference in comorbid conditions, assessed using ICED score, by urine output status, although patients with urine output were more likely to be white and less likely to be referred late for nephrologist care. Third, leadtime bias is important because a random group of dialysis patients with different RKF levels may have had differing durations of renal replacement therapy. Our study design with inclusion of only incident dialysis patients and accurate determination of dialysis start dates overcomes this concern. Individuals with urine output at baseline had a statistically significant, but not clinically relevant, higher eGFR before the start of HD therapy. However, this eGFR difference was not observed at year 1. Fourth, information about dialysis dose (Kt/V) was available for a limited number of participants. Analyses restricted to those with available data yielded results similar to the primary analysis. Fifth, EPO dose data were determined from Medicare claims data and not chart abstraction. Finally, although we show higher inflammation in individuals without urine output at baseline or year 1, the data do not prove causality and it is not possible to deduce temporality of this association.
These limitations are balanced by the strengths of our study, including prospective study design; inclusion of only incident HD patients; detailed and precise information for demographic, clinical, and treatment factors; and a systematic adjudication process for baseline comorbid conditions and outcomes. Availability of these comprehensive data allowed us to adjust extensively for potential confounding by baseline comorbid conditions. Although the possibility of uncontrolled confounding remains, the survival benefit of preserved urine output appears to be independent of most putative confounders. The 2006 KDOQI HD adequacy group had commented that the kinetic effect of RKF in clearing solutes is so powerful that "all possible efforts should be expended to maintain RKF," for example, by avoiding the use of nephrotoxic medications (eg, aminoglycosides and intravenous contrast) in patients on HD therapy who have significant residual urine output. 9 Our results support this opinion expressed in the KDOQI guidelines. In our study, preserved RKF was associated with improved survival compared with loss of RKF over year 1.
In conclusion, this study provides evidence for several beneficial effects of RKF in HD patients. We show a strong and independent relationship between a simply obtained urine output assessment and survival, as well as improved QOL, lower inflammation, and less EPO use in a national prospective cohort study of 734 incident HD patients. Assessment of RKF currently is not part of routine HD care in the United States. These results provide a strong rationale for routine monitoring of RKF in HD patients. Furthermore, the development of methods to assess and
